Howard Sofen

Nov 27, 2024 | jamanetwork.com | April W. Armstrong |Mark Lebwohl |Richard Warren |Howard Sofen

Key PointsQuestion  What is the safety and efficacy of continuous treatment with deucravacitinib over a 3-year period? Findings  In this integrated analysis of the phase 3 POETYK PSO-1, PSO-2, and nonrandomized long-term extension trials in 1519 patients with moderate to severe plaque psoriasis treated through 3 years with 1 or more doses of deucravacitinib, no new safety signals were observed compared with the first year.

Nov 13, 2023 | jofskin.org | Howard Sofen |Stephen K. Tyring |Sandra Johnson |Scott Guenthner

1. Bissonnette R, et al. J Am Acad Dermatol. 2021;84:1059–1067. 2. Lebwohl MG, et al. N Engl J Med. 2021;385:2219–2219. 3. Yasir M, et al. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK531462/. Accessed September 2023. 4. Goh MS, et al. Med J Aust. 2022;216:587–593. 5. Hong JJ, et al. Dermatol Ther (Heidelb). 2021;11:883–844. 6. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022.

Nov 13, 2023 | jofskin.org | April Armstrong |Mark Lebwohl |Richard Warren |Howard Sofen

1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736. 2. Sotyktu [package insert]. Princeton, NJ: Bristol Myers Squibb; September 2022. 3. Sotyktu [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharmaceutical Operations; March 2023. 4. Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K.; September 2022. 5. Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd.; December 2022. 6. Sotyktu [product monograph].

May 7, 2023 | futuremedicine.com | Bruce E. Strober |Diamant Thaçi |Howard Sofen |Leon Kircik

ImmunotherapyAhead of PrintPlain Language Summary of PublicationOpen Access, , , , , , , , , , , , , , & AbstractWhat is this summary about? This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-2, which investigated a new treatment for plaque psoriasis. Plaque psoriasis appears on the body as dry, discolored, patches of skin that can be flaky and covered in scales.

Mar 13, 2023 | jofskin.org | Mark Lebwohl |Richard Warren |Howard Sofen |Shinichi Imafuku

Main Article Content Keywords psoriasis, deucravacitinib, tyrosine kinase 2, phase 3 clinical trial, efficacy, long-term Abstract Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In the pivotal phase 3 POETYK PSO-1 trial, deucravacitinib was superior to placebo and apremilast...